<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=0.60">
  <title>Antihyperglycemic Treatment of Diabetes Mellitus</title>
  <style>
    body {
      font-family: "Segoe UI", Arial, sans-serif;
      background-color: #fafafa;
      color: #222;
      margin: 40px;
      line-height: 1.6;
    }
    h1, h2, h3, h4 {
      color: #0055a4;
    }
    h1 {
      border-bottom: 3px solid #0055a4;
      padding-bottom: 5px;
    }
    table {
      border-collapse: collapse;
      width: 100%;
      margin: 20px 0;
    }
    table, th, td {
      border: 1px solid #ddd;
    }
    th, td {
      padding: 10px;
      text-align: left;
    }
    th {
      background-color: #f2f2f2;
      color: #004477;
    }
    ul {
      margin-left: 25px;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    .note {
      background-color: #eef7ff;
      border-left: 4px solid #007acc;
      padding: 10px 15px;
      margin: 20px 0;
    }
    .highlight {
      background-color: #fff3cd;
      border-left: 4px solid #ffca2c;
      padding: 10px 15px;
      margin: 20px 0;
    }
    .section-divider {
      border-top: 3px dashed #ccc;
      margin: 40px 0;
    }
  </style>
</head>
<body>

  <h1>Antihyperglycemic Treatment of Diabetes Mellitus</h1>

  <h2>Type 1 Diabetes Mellitus (T1DM)</h2>
  <h3>Insulin Replacement Therapy</h3>
  <ul>
    <li><strong>Preferred methods:</strong> Multiple Daily Injections (MDI) or Insulin Pump.</li>
    <li><strong>Starting dose:</strong> 0.4–1.0 units/kg/day (usually 0.5), divided 50% basal + 50% prandial.</li>
    <li><strong>Adjust:</strong> Titrate based on glucose monitoring; reduce during “honeymoon phase.”</li>
    <li><strong>Educate:</strong> Teach carb counting and insulin-to-carb ratios.</li>
  </ul>

  <h3>Other Options</h3>
  <ul>
    <li><strong>Pramlintide:</strong> Amylin analog (rarely used).</li>
    <li><strong>Pancreas or Islet Transplantation:</strong> For recurrent DKA or severe hypoglycemia despite optimal therapy.</li>
  </ul>

  <div class="section-divider"></div>

  <h2>Type 2 Diabetes Mellitus (T2DM)</h2>

  <h3>General Approach</h3>
  <ol>
    <li>Start therapy at diagnosis with lifestyle + pharmacologic treatment.</li>
    <li><strong>Metformin</strong> is first-line unless contraindicated.</li>
    <li>Reassess every 3–6 months; intensify if targets unmet.</li>
    <li>Consider insulin for HbA1c >10%, glucose ≥300 mg/dL, or catabolic symptoms.</li>
  </ol>

  <h3>Noninsulin Diabetes Medications</h3>
  <table>
    <tr>
      <th>Drug Class</th>
      <th>Examples</th>
      <th>Key Points / Dosing</th>
    </tr>
    <tr>
      <td><strong>Biguanide</strong></td>
      <td>Metformin</td>
      <td>Start 500 mg once or twice daily with food → titrate to 2000 mg/day. Avoid if eGFR &lt; 30.</td>
    </tr>
    <tr>
      <td><strong>DPP-4 inhibitors</strong></td>
      <td>Sitagliptin, Saxagliptin, Linagliptin</td>
      <td>Avoid saxagliptin in heart failure; do not combine with GLP-1RAs.</td>
    </tr>
    <tr>
      <td><strong>SGLT-2 inhibitors</strong></td>
      <td>Empagliflozin, Dapagliflozin, Canagliflozin</td>
      <td>Cardiorenal benefits; continue if eGFR ≥20. Risk: genital infections, euglycemic DKA.</td>
    </tr>
    <tr>
      <td><strong>GLP-1 receptor agonists</strong></td>
      <td>Semaglutide, Liraglutide, Dulaglutide</td>
      <td>Preferred in ASCVD, CKD, obesity; promotes weight loss. Start low, titrate slowly.</td>
    </tr>
    <tr>
      <td><strong>Sulfonylureas</strong></td>
      <td>Glimepiride, Glipizide</td>
      <td>Start 1–2 mg/day, max 8 mg/day. Risk of hypoglycemia; avoid in elderly.</td>
    </tr>
    <tr>
      <td><strong>Thiazolidinedione (TZD)</strong></td>
      <td>Pioglitazone</td>
      <td>15–45 mg/day; contraindicated in CHF; beneficial in fatty liver disease.</td>
    </tr>
  </table>

  <div class="note">
    <strong>Expected HbA1c reduction:</strong> ~1% for monotherapy; each added agent lowers HbA1c by 0.7–1.0%.
  </div>

  <div class="section-divider"></div>

  <h2>Insulin Regimens (Detailed)</h2>

  <h3>1. Basal–Bolus Regimen</h3>
  <ul>
    <li><strong>Composition:</strong> 50% basal + 50% bolus insulin (divided among meals).</li>
    <li><strong>Basal:</strong> Glargine, Detemir, Degludec.</li>
    <li><strong>Bolus:</strong> Lispro, Aspart, Glulisine.</li>
    <li><strong>Dosing:</strong> Start TDD 0.4–0.5 units/kg/day.</li>
    <li><strong>Example:</strong> 70 kg → 35 units/day (17 basal + 6 units before each meal).</li>
  </ul>

  <h3>2. Basal-Only Regimen</h3>
  <ul>
    <li><strong>Indication:</strong> Fasting hyperglycemia, elderly, or new-onset T2DM.</li>
    <li><strong>Dose:</strong> 0.1–0.2 units/kg/day (e.g., Glargine at bedtime).</li>
    <li><strong>Titration:</strong> Increase by 2 units every 3 days until fasting glucose 80–130 mg/dL.</li>
  </ul>

  <h3>3. Premixed Regimen</h3>
  <ul>
    <li><strong>Insulins:</strong> 70/30 NPH/Regular, 75/25 Lispro Mix, or 70/30 Aspart Mix.</li>
    <li><strong>Dosing:</strong> Twice daily — before breakfast (2/3) and dinner (1/3).</li>
    <li><strong>Starting:</strong> 0.3–0.5 units/kg/day.</li>
    <li><strong>Pros:</strong> Simpler dosing; <strong>Cons:</strong> Less flexible with meals.</li>
  </ul>

  <h3>4. Correctional (Sliding Scale) Regimen</h3>
  <ul>
    <li><strong>Used:</strong> Hospitalized or acutely ill patients.</li>
    <li><strong>Example (Lispro):</strong>
      <ul>
        <li>150–200 mg/dL → +2 units</li>
        <li>201–250 mg/dL → +4 units</li>
        <li>251–300 mg/dL → +6 units</li>
        <li>&gt;300 mg/dL → +8 units and recheck in 2 hrs</li>
      </ul>
    </li>
  </ul>

  <div class="highlight">
    <strong>Note:</strong> Sliding-scale insulin should not be used alone. Always combine with basal insulin for stable glycemic control.
  </div>

  <div class="section-divider"></div>

  <h2>Choice of Antihyperglycemic Therapy in Comorbidities</h2>

  <table>
    <tr>
      <th>Comorbidity</th>
      <th>Preferred Agents</th>
      <th>Avoid / Caution</th>
      <th>Rationale</th>
    </tr>
    <tr>
      <td><strong>ASCVD (Atherosclerotic Cardiovascular Disease)</strong></td>
      <td>GLP-1 receptor agonists (Liraglutide, Semaglutide, Dulaglutide)<br>SGLT-2 inhibitors (Empagliflozin, Canagliflozin)</td>
      <td>Sulfonylureas, TZDs (may increase CV risk)</td>
      <td>Reduce major adverse cardiac events (MI, stroke, CV death)</td>
    </tr>
    <tr>
      <td><strong>Heart Failure (especially HFrEF)</strong></td>
      <td>SGLT-2 inhibitors (Empagliflozin, Dapagliflozin)</td>
      <td>Thiazolidinediones (Pioglitazone)</td>
      <td>Decrease HF hospitalization and mortality</td>
    </tr>
    <tr>
      <td><strong>Chronic Kidney Disease (CKD)</strong></td>
      <td>SGLT-2 inhibitors (Empagliflozin, Dapagliflozin)<br>GLP-1RA if eGFR &lt; 30</td>
      <td>Metformin if eGFR &lt; 30; Sulfonylureas in advanced CKD</td>
      <td>Slow kidney disease progression and reduce albuminuria</td>
    </tr>
    <tr>
      <td><strong>Obesity / Weight loss needed</strong></td>
      <td>GLP-1RAs (Semaglutide, Liraglutide), SGLT-2 inhibitors</td>
      <td>Sulfonylureas, TZDs, Insulin</td>
      <td>Promote satiety and increase caloric loss in urine</td>
    </tr>
    <tr>
      <td><strong>Cost constraints</strong></td>
      <td>Metformin, Sulfonylureas, TZDs</td>
      <td>Newer agents (GLP-1RA, SGLT2i)</td>
      <td>Affordable and accessible</td>
    </tr>
  </table>

  <div class="note">
    <strong>Clinical tip:</strong> When multiple comorbidities exist, prioritize agents with overlapping benefits (e.g., SGLT2i for both CKD and HF).
  </div>

  <div class="section-divider"></div>

  <h2>Monitoring and Follow-Up</h2>

  <h3>Glycemic Monitoring</h3>
  <ul>
    <li><strong>HbA1c:</strong> Every 3 months if uncontrolled, every 6 months if stable.</li>
    <li><strong>Fasting glucose target:</strong> 80–130 mg/dL.</li>
    <li><strong>Postprandial (2-hr) glucose:</strong> &lt; 180 mg/dL.</li>
    <li><strong>Continuous glucose monitoring (CGM):</strong> Recommended for intensive insulin users.</li>
  </ul>

  <h3>Blood Pressure and Lipids</h3>
  <ul>
    <li><strong>BP goal:</strong> &lt; 130/80 mmHg (ACE inhibitor or ARB preferred).</li>
    <li><strong>Lipid goal:</strong> LDL &lt; 70 mg/dL (statin therapy for all adults ≥40 years).</li>
  </ul>

  <h3>Screening for Complications</h3>
  <ul>
    <li><strong>Eyes:</strong> Annual dilated exam for retinopathy.</li>
    <li><strong>Kidneys:</strong> Urine albumin-to-creatinine ratio yearly.</li>
    <li><strong>Feet:</strong> Comprehensive foot exam yearly (more often if neuropathy).</li>
    <li><strong>Neuropathy:</strong> Assess vibration and monofilament sensation yearly.</li>
  </ul>

  <h3>Patient Education</h3>
  <ul>
    <li>Diet: Balanced carbohydrate intake, limited refined sugars.</li>
    <li>Exercise: ≥150 min/week moderate-intensity.</li>
    <li>Smoking cessation and weight management.</li>
    <li>Vaccinations: Annual influenza + COVID-19; pneumococcal and hepatitis B as indicated.</li>
  </ul>

  <div class="note">
    <strong>Follow-up frequency:</strong> Typically every 3 months until stable, then every 6 months.
  </div>

  <div class="section-divider"></div>

  <h3>References</h3>
  <ol>
    <li><a href="https://www.amboss.com/us/knowledge/diabetes-mellitus?utm_medium=chatgpt-plugin&utm_source=chatgpt" target="_blank">Diabetes Mellitus – Glycemic Treatment (AMBOSS)</a></li>
    <li><a href="https://www.amboss.com/us/knowledge/diabetes-mellitus-in-pregnancy?utm_medium=chatgpt-plugin&utm_source=chatgpt" target="_blank">Diabetes Mellitus in Pregnancy (AMBOSS)</a></li>
  </ol>

</body>
</html>